TARS

Tarsus to Participate at Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 5, 2024
Tarsus, TARS, Science, Conference, Patient, Telluride, Management

ET

Key Points: 
  • ET
    Barclays Global Healthcare Conference (Miami, FL)
    Jeff Farrow, Chief Financial Officer and Chief Strategy Officer, and Sesha Neervannan, Chief Operating Officer, will participate in a fireside chat on Tuesday, March 12, 2024, at 12:05 p.m. PT / 3:05 p.m.
  • Please check the Tarsus website for the latest information.
  • A live webcast of the fireside chats will be available on the events section of the Tarsus website.
  • The replay will be available within 48 hours and will be archived for a limited time.

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Retrieved on: 
Tuesday, March 5, 2024
Education, Inflammation, FDA, Irritation, MITES, Blepharitis, OD, Patient, Disease, Eyelid, Diagnosis, Science, Infestation, Human, TARS, Pharmaceutical industry

“Mite Party” is designed to elevate consumer awareness of Demodex blepharitis through relatable messaging and compelling visuals to encourage patients who may have Demodex blepharitis to seek out an eye care provider for screening.

Key Points: 
  • “Mite Party” is designed to elevate consumer awareness of Demodex blepharitis through relatable messaging and compelling visuals to encourage patients who may have Demodex blepharitis to seek out an eye care provider for screening.
  • “We are committed to increasing Demodex blepharitis education and awareness so that patients more effectively understand their disease and are motivated to seek treatment,” said Aziz Mottiwala, Chief Commercial Officer of Tarsus.
  • We look forward to advancing this novel campaign with the goal of helping as many patients with Demodex blepharitis as possible.”
    Demodex blepharitis occurs when Demodex mites – the most common ectoparasites found on humans – overpopulate on the eyelids.
  • “Mite Party” will officially launch on the XDEMVY Facebook page (@xdemvyrx) with a live event designed to “break up the mite parties” on Demodex blepharitis patients’ eyelids.

Tarsus Announces Pricing of $100.0 Million Public Offering

Retrieved on: 
Friday, March 1, 2024
Tarsus, Attention, Prospectus, Telephone, File, Floor, Sale, Exercise, Broad Street, Madison Avenue, Patient, BofA Securities, Science, Guggenheim Partners, Oppenheimer Holdings, TARS, Security (finance)

In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $100.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
  • The offering is expected to close March 5, 2024, subject to the satisfaction of customary closing conditions.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Tarsus Announces Proposed $100.0 Million Public Offering

Retrieved on: 
Thursday, February 29, 2024
Tarsus, Attention, Prospectus, Telephone, File, Floor, Sale, Broad Street, Madison Avenue, Patient, BofA Securities, Science, Guggenheim Partners, Oppenheimer Holdings, TARS, Security (finance)

Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.

Key Points: 
  • Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.
  • All securities in the proposed offering are to be sold by Tarsus.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

Retrieved on: 
Thursday, February 22, 2024
Lyme disease, Probability, Science, Mortality, Skin, Tick, Volunteering, Patient, TARS

Sterile, non-pathogenic nymphal ticks were placed on the skin of healthy human volunteers at two separate instances (one day prior to dosing and on Day 30 after dosing).

Key Points: 
  • Sterile, non-pathogenic nymphal ticks were placed on the skin of healthy human volunteers at two separate instances (one day prior to dosing and on Day 30 after dosing).
  • In most cases, ticks must be attached for 36-48 hours or more before Lyme disease can be transmitted, so killing ticks within 24 hours of attachment can greatly increase the probability of disease prevention 1.
  • Both the high and low doses of TP-05 demonstrated a statistically significant benefit in killing ticks compared to placebo.
  • No statistically significant differences in tick mortality were observed between the two TP-05 treatment arms, and TP-05 was generally well tolerated.

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

Retrieved on: 
Tuesday, February 20, 2024
Science, Webcast, Patient, TARS

IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m.

Key Points: 
  • IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m.
  • ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
  • Participants may access the webcast here .
  • A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for at least 90 days.

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

Retrieved on: 
Wednesday, January 31, 2024
TARS, Patient, Tarsus, Science

IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the Sixth Annual Guggenheim Healthcare Talks conference in New York City at 1:00 p.m.

Key Points: 
  • IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the Sixth Annual Guggenheim Healthcare Talks conference in New York City at 1:00 p.m.
  • ET on Thursday, February 8, 2024.
  • A live webcast of the fireside chat can be accessed on the events section of the Tarsus website.
  • Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

Retrieved on: 
Monday, December 11, 2023
Science, Food, BID, TID, Disease, Meibomian gland, TARS, Demodex, MGD, Patient, Pharmaceutical industry

Collarette cure and lid margin erythema cure results were also statistically significant and consistent with the results of previous TP-03 studies.

Key Points: 
  • Collarette cure and lid margin erythema cure results were also statistically significant and consistent with the results of previous TP-03 studies.
  • No statistically significant differences were observed between the BID and TID treatment arms and TP-03 was well tolerated.
  • “We are encouraged by these early results, which underscore the potential of TP-03 to address the underlying cause of disease,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
  • “We look forward to further analyzing the data from this trial and continued discussions with the U.S. Food and Drug Administration about the best path forward for TP-03 in MGD.”

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Retrieved on: 
Thursday, November 9, 2023
DB, Food, Eyelid, MITES, Disease, American Academy, Patient, PPP, ECP, FDA, Science, Optometry, TARS, American Academy of Optometry, American Academy of Ophthalmology, PDUFA, Pharmaceutical industry, Demodex, Ophthalmology

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the third quarter ended September 30, 2023, and recent business achievements.

Key Points: 
  • Management to host conference call today, November 9, 2023, at 1:30 p.m. P.T.
  • IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the third quarter ended September 30, 2023, and recent business achievements.
  • Saturn-2 data were delivered as encore presentations at the American Academy of Optometry and American Academy of Ophthalmology conferences.
  • In the third quarter of 2023:
    The Company’s expansive disease education efforts continue to drive awareness among eye care providers (ECPs) and action in proactively diagnosing DB.

QinetiQ US Awarded $170M U.S. Customs and Border Protection contract for Tethered Aerostat Radar System (TARS)

Retrieved on: 
Monday, November 20, 2023
United States Customs Service, Woman, CBP, Atmosphere of Earth, History, Data analysis, Straits of Florida, AMO, TARS, Atmosphere, Qinetiq, Customs, DHS, Radar, Drug, Risk management

MCLEAN, Va., Nov. 20, 2023 /PRNewswire/ -- QinetiQ US, has received a U.S. Department of Homeland Security (DHS) Customs and Border Protection (CBP) Air and Marine (AMO) Tethered Aerostat Radar System (TARS) Operations & Maintenance (O&M) III contract, comprising one base with four option years, valued at $170M.

Key Points: 
  • To support national security missions along the southern border, U.S. Customs and Border Protection awards TARS to Avantus Federal (now QinetiQ US).
  • MCLEAN, Va., Nov. 20, 2023 /PRNewswire/ -- QinetiQ US, has received a U.S. Department of Homeland Security (DHS) Customs and Border Protection (CBP) Air and Marine (AMO) Tethered Aerostat Radar System (TARS) Operations & Maintenance (O&M) III contract, comprising one base with four option years, valued at $170M.
  • Employing tethered aerostats, TARS operators relay vital data to DHS to support monitoring border activity in real time.
  • This data is also shared with the U.S. military and law enforcement partners conducting related air, land, and maritime missions.